Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457700 | 0.99 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL8071013 | 0.98 | AGTR1 (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL30458105 | 0.91 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL21083588 | 0.91 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL29726894 | 0.91 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6092394 | 0.90 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL60 | 0.90 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL29383742 | 0.90 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL14286268 | 0.90 | AGTR1 (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL3216357 | 0.89 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1049116-C | Process for treating cardiovascular hypertrophy and hyperplasia | HOECHST AG (DE) | 2000-02-09 | — | — | CN | claimed |
| CN-1062289-A | The treatment heart, blood vessel hypertrophy and outgrowth method | HOECHST AG (DE) | 1992-07-01 | — | — | CN | claimed |
| CN-102335172-B | Amlodipine and losartan potassium medicinal composition and preparation method thereof | HAINAN JINRUI PHARMACEUTICAL | 2012-12-12 | — | — | CN | disclosed |
| CN-102335172-A | Amlodipine and losartan potassium medicinal composition and preparation method thereof | HAINAN JINRUI PHARMACEUTICAL | 2012-02-01 | — | — | CN | disclosed |
| EP-1019048-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | Merck Sharp Dohme (Italia) S.P.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| CN-1049116-C | Process for treating cardiovascular hypertrophy and hyperplasia | HOECHST AG (DE) | 2000-02-09 | — | — | CN | disclosed |
| WO-1999016437-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME (ITALIA) S.P.A. (IT) | 1999-04-08 | — | — | WO | disclosed |
| CN-1062289-A | The treatment heart, blood vessel hypertrophy and outgrowth method | HOECHST AG (DE) | 1992-07-01 | — | — | CN | disclosed |